gallery 07 · about the project
About Medicine Wolverine
A gallery of the published BPC-157 TB-500 record, hung study by study — and an explicit account of what this project is and is not.
What this project is
Medicine Wolverine is a gallery of the peer-reviewed research literature on BPC-157 TB-500 — the two-peptide research blend pairing BPC-157 with TB-500 — hung study by study. Nothing is sold, supplied, or dispensed here; no clinician is on staff; and no line on the site is medical advice, a prescription, or a treatment recommendation.
The site is built as a gallery for a reason. The blend's evidence is a heterogeneous collection drawn from two separate constituent literatures — a tendon study, an angiogenesis finding, an actin crystal structure, a human safety dataset, a pharmacokinetic profile — with no controlled combination trial binding them. A gallery is the honest vessel for that: it presents the record study by study, each item tagged with which leg of the blend it belongs to and what its evidence status is, rather than pretending a single coherent dataset exists.
What 'medicine' means in the name
The word "medicine" in this site's name is editorial framing — a position the publisher takes toward the literature and toward the question of medicinal access, not a claim about services we offer. We do not run a clinic, a pharmacy, or a telehealth practice. We do not diagnose, treat, prescribe, or consult. What "medicine" signals here is the register we read in: alongside the research, we surface where medicinal access actually stands — the FDA 503A compounding status, the WADA position, and the regulatory landscape — as documented, cited facts. That is the distinction this page draws explicitly, so it is not mistaken for anything else.
How we handle the evidence
Every quantitative claim on this site cites a specific study, and the references page lists each one with its DOI and source link. Where the data is precise — BPC-157's elimination half-life under 30 minutes in animal pharmacokinetics [5], the one-to-one actin binding resolved by crystallography [3] — we state it precisely. Where it is absent — no controlled combination trial, no validated blend dose, no human data for the TB-500 heptapeptide itself [8][9] — we state that just as plainly. We do not present community protocols as validated dosing, and we use only generic compound names. The editorial posture is simple: the published record, read first, and the gaps named as clearly as the findings.